Zimislecel, a novel allogeneic stem cell-derived islet cell therapy, has demonstrated encouraging results in people with Type 1 diabetes. This autoimmune condition destroys insulin-producing beta cells, forcing patients to rely on lifelong insulin therapy and exposing them to the risk of severe hypoglycaemia. A recent early-stage trial aimed to evaluate the safety and efficacy of zimislecel in restoring islet function. Notably, 83% of participants who received the full dose no longer required insulin after one year.
Trial Design and Dosing Strategy
As reported by the European Medical Journal, he phase 1–2 clinical trial enrolled 14 participants, dividing them into three groups.
- Part A: Two participants received a half dose (0.4×10⁹ cells) with the option for a second dose within two years.
- Parts B and C: Twelve participants received a single full dose (0.8×10⁹ cells).
All participants received glucocorticoid-free immunosuppressive therapy. The primary outcome in part C was the absence of severe hypoglycaemic events between days 90 and 365, along with improved HbA1c to below 7% or at least a one-percentage-point reduction from baseline between days 180 and 365. Researchers measured C-peptide levels to track islet function and engraftment.
Key Findings
At baseline, none of the participants had detectable C-peptide. Post-treatment, all 14 showed evidence of islet engraftment and functional activity. Among the full-dose group:
- 100% avoided severe hypoglycaemic events and met HbA1c targets.
- Participants spent over 70% of their time within the optimal glucose range (70–180 mg/dL).
- 83% (10 out of 12) achieved complete insulin independence at one year.
Safety Profile and Adverse Events
Neutropenia emerged as the most common serious adverse event, affecting three participants. Two deaths occurred during the study—one from cryptococcal meningitis and another from complications related to severe pre-existing neurocognitive decline.
Clinical Implications and Future Directions
These early results indicate that zimislecel could significantly alter Type 1 diabetes treatment by restoring natural insulin production. However, the trial’s small sample size and short follow-up limit the ability to generalise findings. Larger, longer-term studies are essential to confirm safety, durability, and scalability of the therapy.
Clinicians should exercise caution but remain attentive to future evidence, as this approach could eventually redefine insulin management for patients with Type 1 diabetes.